Saturday 17 October 2026
Export VAXX’s income statement to Excel — free account
Vaxxinity, Inc.
VAXX Healthcare Biotechnology
0.00
0.00
NaN
Follow VAXX
| Dec '23 | Sep '23 | Jun '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
| (150.65%) | (126.96%) | (108.96%) | (94.94%) |
+8 more TTM periods Free account |
|
| (75.55%) | (73.15%) | (69.21%) | (64.69%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(213.19%) | (183.75%) | (151.52%) | (127.62%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.46) | (0.48) | (0.47) | (0.46) | |
Free Cash Flow |
(58.04) | (60.55) | (58.96) | (57.79) | |
Capital Expenditures |
(0.80) | (0.68) | (0.88) | (1.32) | |
| Other line items | |||||
Cash ROIC |
(101.52%) | (77.23%) | (57.02%) | (45.68%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.74 | 1.86 | 0.87 | |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 468.30 | 333.63 | 566.68 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(83.74) | (44.18) | (57.50) | (63.75) | |
Operating CF/Net income |
1.01 | 0.91 | 0.81 | 0.75 | |
Depreciation/Fixed assets |
0.07 | 0.05 | 0.02 | 0.05 | |
Capex/Depreciation |
(1.10) | (1.24) | (3.83) | (2.36) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.47) | (0.46) | (0.45) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates